Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IONS
IONS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IONS News
Ionis Pharmaceuticals to Host Webcast on February 25 for Q4 and Full Year 2025 Results
4d ago
Newsfilter
Clinical Benefits of High-Dose Nusinersen Confirmed in DEVOTE Study
Feb 04 2026
Globenewswire
Clinical Findings on High-Dose Nusinersen Published
Feb 04 2026
Newsfilter
Ionis Pharmaceuticals Insider Sold Shares Worth $323,490, According to a Recent SEC Filing
Jan 23 2026
Yahoo Finance
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
Jan 21 2026
Benzinga
Ionis Pharmaceuticals and Otsuka Gain EU Approval for Dawnzera to Treat Hereditary Angioedema
Jan 21 2026
seekingalpha
Ionis Pharmaceuticals and Otsuka Get EU Approval for Dawnzera, Securing $15M Milestone Payment
Jan 21 2026
NASDAQ.COM
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
Jan 19 2026
seekingalpha
Ionis' Tryngolza Set to Become First Blockbuster Drug with Peak Revenue Potential of $2 Billion
Jan 14 2026
Yahoo Finance
ARK Invest Focuses on Innovation Themes, Increases Stake in Komatsu and Others
Jan 12 2026
seekingalpha
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
Jan 08 2026
Yahoo Finance
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
Jan 08 2026
Yahoo Finance
Ionis and GSK Share Pivotal Phase 3 Data for Bepirovirsen in Chronic Hepatitis B
Jan 07 2026
Benzinga
Ionis and GSK Report Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment
Jan 07 2026
Businesswire
Ionis and GSK's Bepirovirsen Shows Significant Functional Cure Rate in Chronic Hepatitis B Trials
Jan 07 2026
Newsfilter
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
Dec 31 2025
Benzinga
Show More News
